These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 8410125

  • 1. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
    Seiter K, Feldman EJ, Halicka HD, Traganos F, Darzynkiewicz Z, Lake D, Ahmed T.
    J Clin Oncol; 1997 Jan; 15(1):44-51. PubMed ID: 8996123
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
    Lejeune C, Tubiana N, Gastaut JA, Maraninchi D, Richard B, Launay MC, Sainty D, Sebahoun G, Carcassonne Y.
    Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
    [Abstract] [Full Text] [Related]

  • 7. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
    Linkesch W, Thaler J, Gattringer C, Konwalinka G.
    Haematol Blood Transfus; 1990 Apr; 33():330-2. PubMed ID: 2323638
    [No Abstract] [Full Text] [Related]

  • 8. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
    Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, Razis ED.
    Leukemia; 1991 Aug; 5(8):712-4. PubMed ID: 1886423
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C.
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [Abstract] [Full Text] [Related]

  • 12. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W.
    Cancer; 1997 Jan 01; 79(1):59-68. PubMed ID: 8988727
    [Abstract] [Full Text] [Related]

  • 13. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A.
    Cancer; 2007 Apr 15; 109(8):1543-9. PubMed ID: 17340589
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM.
    J Clin Oncol; 2003 Mar 15; 21(6):1050-6. PubMed ID: 12637470
    [Abstract] [Full Text] [Related]

  • 15. [Preliminary results of the treatment of acute leukemia with mitoxantrone].
    Rozmysłowicz T, Pałynyczko G, Mazur J, Konecki R, Apel D, Mariańska B, Maj S, Hołowiecki J, Rudzka E, Lawniczek T.
    Acta Haematol Pol; 1991 Mar 15; 22(1):69-81. PubMed ID: 1823970
    [Abstract] [Full Text] [Related]

  • 16. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2012 Aug 15; 12(4):244-51. PubMed ID: 22534616
    [Abstract] [Full Text] [Related]

  • 17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S, Picardi A, Fazi P, Testi AM, Petti MC, Montefusco E, Mandelli F.
    Leukemia; 1996 May 15; 10(5):766-8. PubMed ID: 8656669
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DA.
    Cancer Treat Rep; 1987 Feb 15; 71(2):161-3. PubMed ID: 3467843
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
    Dutcher JP, Morris EL, Gaynor B, Paietta E, Wiernik PH.
    Med Oncol; 2010 Sep 15; 27(3):728-35. PubMed ID: 19697165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.